Insight Molecular Diagnostics (IMDX) Retained Earnings (2015 - 2026)

Insight Molecular Diagnostics has reported Retained Earnings for 12 years, with the latest figure at -$405.1 million in Q1 2026.

• Quarterly Retained Earnings fell 13.39% year-over-year to -$405.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$405.1 million (down 13.39% YoY) and the FY2025 annual result came in at -$400.8 million, down 1908485.71% from the prior year.
• Retained Earnings eased to -$405.1 million in Q1 2026 per IMDX's latest filing, from -$400.8 million in the prior quarter.
• Over five years, Retained Earnings peaked at $57000.0 in Q3 2024 and troughed at -$405.1 million in Q1 2026.
• A 5-year average of -$202.5 million and a median of -$262.1 million in 2023 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings jumped 100.02% in 2022, then slumped 1908485.71% in 2025.
• Over 5 years, Retained Earnings stood at -$260.7 million in 2022, then decreased by 11.2% to -$289.9 million in 2023, then jumped by 100.01% to $21000.0 in 2024, then plunged by 1908485.71% to -$400.8 million in 2025, then slipped by 1.07% to -$405.1 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$405.1 million, -$400.8 million, and -$377.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.